Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids

Authors: Loureiro LR, Sousa DP, Ferreira D, Chai W, Lima L, Pereira C, Lopes CB, Correia VG, Silva LM, Li C, Santos LL, Ferreira JA, Barbas A, Palma AS, Novo C, Videira PA
Publication Year: 2018
Journal: Scientific Reports
Link: https://www.nature.com/articles/s41598-018-30421-w

Incomplete O-glycosylation is a feature associated with malignancy resulting in the expression of truncated glycans such as the sialyl-Tn (STn) antigen. Despite all the progress in the development of potential anti-cancer antibodies, their application is frequently hindered by low specificities and cross-reactivity. In this study, a novel anti-STn monoclonal antibody named L2A5 was developed by hybridoma […]
Read More

Protein Disulfide Isomerases: Impact of Thapsigargin treatment on their expression in melanoma cell lines

Authors: Novo C, Silva Z, Veríssimo T, Videira PA
Publication Year: 2015
Journal: International Journal of Biological Macromolecules
Link: https://www.sciencedirect.com/science/article/pii/S0141813015002676?via%3Dihub

Anti-cancer treatments usually elevate the content of unfolded or misfolded proteins in the endoplasmic reticulum (ER). Here we aimed to get insights into the relation between sensitivity of melanoma cell lines to the ER stress inducer thapsigargin (THG) and the genetic expression of protein disulfide isomerase family members (PDIs). The expression of PDIs was analysed […]
Read More

Challenges in Antibody Development against Tn and Sialyl-Tn Antigens

Authors: Barbas A, Carrascal MA, Delannoy P, Loureiro LR, Novo C, Ramalho JS, Videira PA
Publication Year: 2015
Journal: Biomolecules
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598775/%20

The carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas and usually absent in healthy tissues. These antigens have been correlated with cancer progression and poor prognosis, and associated with immunosuppressive microenvironment. Presently they are used in clinical trials as therapeutic vaccination, but with limited success due to their low immunogenicity. Alternatively, anti-Tn […]
Read More

Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids

Protein Disulfide Isomerases: Impact of Thapsigargin treatment on their expression in melanoma cell lines

Challenges in Antibody Development against Tn and Sialyl-Tn Antigens

About GHTM

Contacts

Map